ZVRA Zevra Therapeutics Inc

Price (delayed)

$5.95

Market cap

$215.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.15

Enterprise value

$217.05M

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes ...

Highlights
ZVRA's revenue has soared by 54% YoY
ZVRA's gross profit is up by 48% YoY
The quick ratio has declined by 36% year-on-year but it has increased by 12% since the previous quarter
Zevra Therapeutics's EPS has decreased by 29% YoY and by 22% QoQ
Zevra Therapeutics's equity has decreased by 28% YoY

Key stats

What are the main financial stats of ZVRA
Market
Shares outstanding
36.22M
Market cap
$215.5M
Enterprise value
$217.05M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.99
Price to sales (P/S)
12.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.1
Earnings
Revenue
$16.56M
EBIT
-$39.19M
EBITDA
-$38.67M
Free cash flow
-$22.1M
Per share
EPS
-$1.15
Free cash flow per share
-$0.64
Book value per share
$1.99
Revenue per share
$0.48
TBVPS
$4
Balance sheet
Total assets
$138.98M
Total liabilities
$71.51M
Debt
$44.82M
Equity
$67.47M
Working capital
$115.3M
Liquidity
Debt to equity
0.66
Current ratio
6.31
Quick ratio
6.23
Net debt/EBITDA
-0.04
Margins
EBITDA margin
-233.5%
Gross margin
93.4%
Net margin
-241%
Operating margin
-266.8%
Efficiency
Return on assets
-34.2%
Return on equity
-54.5%
Return on invested capital
-57.8%
Return on capital employed
-33.4%
Return on sales
-236.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZVRA stock price

How has the Zevra Therapeutics stock price performed over time
Intraday
0.17%
1 week
1.88%
1 month
-13.27%
1 year
9.98%
YTD
-9.16%
QTD
-9.16%

Financial performance

How have Zevra Therapeutics's revenue and profit performed over time
Revenue
$16.56M
Gross profit
$15.47M
Operating income
-$44.19M
Net income
-$39.92M
Gross margin
93.4%
Net margin
-241%
ZVRA's revenue has soared by 54% YoY
ZVRA's gross profit is up by 48% YoY
ZVRA's net margin is up by 27% year-on-year but it is down by 23% since the previous quarter
The operating income has contracted by 25% from the previous quarter and by 22% YoY

Growth

What is Zevra Therapeutics's growth rate over time

Valuation

What is Zevra Therapeutics stock price valuation
P/E
N/A
P/B
2.99
P/S
12.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.1
Zevra Therapeutics's EPS has decreased by 29% YoY and by 22% QoQ
Zevra Therapeutics's equity has decreased by 28% YoY
The price to book (P/B) is 25% higher than the last 4 quarters average of 2.4
ZVRA's revenue has soared by 54% YoY
ZVRA's P/S is 38% above its 5-year quarterly average of 9.0 but 11% below its last 4 quarters average of 14.0

Efficiency

How efficient is Zevra Therapeutics business performance
ZVRA's ROE has shrunk by 71% YoY and by 34% QoQ
Zevra Therapeutics's return on invested capital has increased by 38% YoY and by 7% QoQ
Zevra Therapeutics's return on sales has increased by 29% YoY but it has decreased by 22% QoQ
The company's return on assets fell by 22% YoY and by 18% QoQ

Dividends

What is ZVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZVRA.

Financial health

How did Zevra Therapeutics financials performed over time
The total assets is 94% greater than the total liabilities
The total liabilities has soared by 178% YoY and by 93% from the previous quarter
The company's current ratio fell by 38% YoY but it rose by 11% QoQ
ZVRA's debt is 34% smaller than its equity
Zevra Therapeutics's equity has decreased by 28% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.